Loading
PSMA scans could measure prostate cancer burden and response far better than PSA, but no one has done the standardisation work to make the measurement trustworthy across scanners.
Total PSMA-positive tumour volume and SUV metrics predict outcome in metastatic prostate cancer and response to radioligand therapy, but acquisition, reconstruction and segmentation vary between centres. A QIBA-style profile (phantom calibration, harmonised reconstruction, validated segmentation software) followed by biomarker qualification for defined contexts of use (prognosis, response assessment) would let PSMA volume be used as an endpoint and selection tool in trials.
Shares Total-body PET for personalised radioligand dosing, Prostate cancer.
Shares PET/CT, Prostate cancer.
Shares PSMA PET, PET/CT, Prostate cancer.
Shares PSMA PET, Prostate cancer.
Shares PET/CT, Prostate cancer.
Shares PET/CT, Prostate cancer.
Shares PET/CT, Prostate cancer.
Shares PSMA PET, PET/CT, Prostate cancer.